Prebiotic treatment in experimental colitis reduces the risk of colitic cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 8, 2011, Pages 1298-1308

  Komiyama, Yutaka ^a   Mitsuyama, Keiichi ^b   Masuda, Jyunya ^b   Yamasaki, Hiroshi ^b   Takedatsu, Hidetoshi ^b   Andoh, Akira ^c   Tsuruta, Osamu ^b   Fukuda, Masanobu ^d   Kanauchi, Osamu ^a  

^a KIRIN HOLDINGS CO LTD   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d NIHON UNIVERSITY   (Japan)

Author keywords

Colitic cancer; Germinated barley footstuff; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

BETA GLUCOSIDASE; CARBOXYLIC ACID; CYCLINE; DEXTRAN SULFATE; PREBIOTIC AGENT; SUCCINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; CANCER INCIDENCE; CECUM; COLITIS; COLON; COLON ADENOMA; COLON ADENOMATOUS DYSPLASIA; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DIET; DYSPLASIA; ENZYME ACTIVITY; FOOD; GERMINATED BARLEY FOODSTUFF; HISTOPATHOLOGY; LABELING INDEX; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RISK REDUCTION; SCORING SYSTEM; SQUAMOUS EPITHELIUM; STRATIFIED SQUAMOUS EPITHELIUM;

EID: 79960470036     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06690.x     Document Type: Article

References (39)

1. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-33.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006; 3: 390-407.
3. Seksik P, Sokol H, Lepage P etal. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2006; 24 (Suppl. 3): 11-18.
4. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M. Antimicrobials in the management of inflammatory bowel disease. Digestion 2006; 73 (Suppl. 1): 77-85.
5. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol. Nutr. Food Res. 2005; 49: 601-8.
6. Kanauchi O, Suga T, Tochihara M etal. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J. Gastroenterol. 2002; 37 (Suppl. 14): 67-72.
7. Mitsuyama K, Saiki T, Kanauchi O etal. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment. Pharmacol. Ther. 1998; 12: 1225-30.
8. Hanai H, Kanauchi O, Mitsuyama K etal. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int. J. Mol. Med. 2004; 13: 643-7.
9. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
10. Rutter MD, Saunders BP, Wilkinson KH etal. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-6.
11. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004; 287: G7-17.
12. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008; 135: 1442-7.
13. Kanauchi O, Mitsuyama K, Andoh A, Iwanaga T. modulation of intestinal environment by prebiotic germinated barley foodstuff prevents chemo-induced colonic carcinogenesis in rats. Oncol. Rep. 2008; 20: 793-801.
14. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J. Gastroenterol. Hepatol. 2002; 17: 818-24.
15. Kanauchi O, Serizawa I, Araki Y etal. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J. Gastroenterol. 2003; 38: 134-41.
16. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig. Dis. Sci. 2002; 47: 1266-78.
17. Mudter J, Amoussina L, Schenk M etal. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 2008; 118: 2415-26.
18. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev. Res. 2008; 1: 376-84.
19. Djouzi Z, Andrieux C, Degivry MC, Bouley C, Szylit O. The association of yogurt starters with Lactobacillus casei DN 114.001 in fermented milk alters the composition and metabolism of intestinal microflora in germ-free rats and in human flora-associated rats. J. Nutr. 1997; 127: 2260-6.
20. Cheon JH, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis. Inflamm. Bowel Dis. 2006; 12: 1152-61.
21. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J. Cell Sci. 2003; 116: 3051-60.
22. Carpenter HA, Talley NJ. The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Am. J. Gastroenterol. 2000; 95: 878-96.
23. Rowland IR, Rumney CJ, Coutts JT, Lievense LC. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 1998; 19: 281-5.
24. Rowland IR, Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faecal microflora. J. Appl. Bacteriol. 1993; 74: 667-74.
25. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol. Biomarkers Prev. 2003; 12: 933-9.
26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
27. Ishikawa TO, Herschman HR. Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010; 31: 729-36.
28. Kweon MN, Takahashi I, Yamamoto M, Jang MH, Suenobu N, Kiyono H. Development of antigen induced colitis in SCID mice reconstituted with spleen derived memory type CD4(+) CD45RB(+) T cells. Gut 2002; 50: 299-306.
29. Horwitz BH. The straw that stirs the drink: insight into the pathogenesis of inflammatory bowel disease revealed through the study of microflora-induced inflammation in genetically modified mice. Inflamm. Bowel Dis. 2007; 13: 490-500.
30. Araki Y, Andoh A, Koyama S, Fujiyama Y, Kanauchi O, Bamba T. Effects of germinated barley foodstuff on microflora and short chain fatty acid production in dextran sulfate sodium-induced colitis in rats. Biosci. Biotechnol. Biochem. 2000; 64: 1794-800.
31. Van der Meulen R, Makras L, Verbrugghe K, Adriany T, De Vuyst L. In vitro kinetic analysis of oligofructose consumption by Bacteroides and Bifidobacterium spp. indicates different degradation mechanisms. Appl. Environ. Microbiol. 2006; 72: 1006-12.
32. Hata K, Andoh A, Sato H etal. Sequential changes in luminal microflora and mucosal cytokine expression during developing of colitis in HLA-B27/beta2-microglobulin transgenic rats. Scand. J. Gastroenterol. 2001; 36: 1185-92.
33. Martinez C, Antolin M, Santos J etal. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am. J. Gastroenterol. 2008; 103: 643-8.
34. Yamamura M. [Faecal microflora of patients with ulcerative colitis]. Nippon Shokakibyo Gakkai Zasshi 1987; 84: 2669-80.
35. Fukui S, Shimoyama T, Tamura K, Yamamura M, Satomi M. Mucosal blood flow and generation of superoxide in rat experimental colitis induced by succinic acid. J. Gastroenterol. 1997; 32: 464-71.
36. Kanbe T, Murai R, Mukoyama T etal. Naked gene therapy of hepatocyte growth factor for dextran sulfate sodium-induced colitis in mice. Biochem. Biophys. Res. Commun. 2006; 345: 1517-25.
37. Risio M. Cell proliferation in colorectal tumor progression: an immunohistochemical approach to intermediate biomarkers. J. Cell. Biochem. 1992; 16G: 79-87.
38. Talero E, Sanchez-Fidalgo S, Villegas I, de la Lastra CA, Illanes M, Motilva V. Role of different inflammatory and tumor biomarkers in the development of ulcerative colitis-associated carcinogenesis. Inflamm. Bowel Dis. 2011; 17: 696-710.
39. Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol. Ther. 2006; 5: 1265-9.